Full-Time

AI-Enabled Manufacturing Innovation Director

Updated on 8/23/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Limited, periodic travel is required for global stakeholder engagement.

Category
Biology & Biotech (1)
Required Skills
LLM
Product Management
Risk Management
Data Analysis

Get referred to Amgen

See people who can refer or advise you

Requirements
  • 18 to 23 years of experience leading digital enablement, product delivery, operational transformation, and/or capability building in a regulated environment, preferably biopharma or manufacturing.
  • Demonstrated success building and leading teams, including leader-first hiring and scaling new organizations.
  • Strong fluency in product management and modern delivery practices, including roadmapping, prioritization, user-centered design, and adoption at scale.
  • Practical understanding of applying artificial intelligence and advanced analytics in enterprise settings, including governance, controls, and value measurement.
  • Strong working knowledge of GxP expectations, audit readiness, and delivering solutions in regulated operations while partnering effectively with Quality and compliance stakeholders.
  • Proven ability to influence across a complex global network without direct authority, with strong executive communication and stakeholder management.
  • Experience operating within governance and funding release mechanisms, with disciplined planning, reporting, and escalation.
Responsibilities
  • Define and implement the Innovation Velocity Interface strategy and operating model aligned to manufacturing transformation priorities and enterprise standards.
  • Establish a repeatable delivery lifecycle from intake through prioritization, prototyping, validation, scaling, and sustainment, with clear readiness and decision gates.
  • Translate business objectives into a prioritized portfolio of capabilities with measurable outcomes and a sustainable roadmap.
  • Lead a portfolio of digital and data-enabled capabilities that improve operational effectiveness, visibility, standardization, and scalability across the manufacturing network.
  • Apply a generative and agentic artificial-intelligence-first mindset to solution discovery and delivery while ensuring appropriate controls, data integrity, and responsible use.
  • Drive disciplined execution across requirements, design, build partnership, testing, deployment, stabilization, and ongoing enhancement.
  • Ensure delivery is executed within required GxP and regulatory expectations, validation practices, and audit-ready documentation standards.
  • Partner with Quality and business stakeholders to ensure appropriate decision-making, evidence capture, and compliance by design.
  • Maintain active risk, issue, and dependency management, escalation discipline, and routine executive reporting.
  • Serve as a trusted partner to manufacturing sites and functions, ensuring solutions are anchored in real operational needs and adoption requirements.
  • Ensure end-user engagement for requirements and testing is structured, efficient, and minimizes burden on site teams while preserving critical expertise.
  • Build strong cross-functional alignment across manufacturing, technology delivery, and quality organizations.
  • Hire, onboard, and develop a high-performing team in AIN, including product and engagement leadership, product owners, and supporting roles.
  • Build a culture of innovation, accountability, learning, and execution excellence balanced with rigor for regulated operations.
  • Establish clear role expectations, performance management, and capability development pathways for the Innovation Velocity Interface organization.
  • Ensure scaled capabilities are stabilized, adopted, and sustained with clear ownership, support models, and enhancement backlogs.
  • Track outcomes and operational performance through key performance indicators such as adoption health, cycle-time improvement, standardization, quality of insights, and execution reliability.
  • Capture lessons learned from deployments and continuously improve the Innovation Velocity Interface delivery model and governance.
Desired Qualifications
  • Biopharma or manufacturing experience is preferred.
  • Travel as needed to support global stakeholder engagement, limited and periodic.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $10.1 billion, up 10%, and guidance rose to $39.4 billion.
  • Repatha, Evenity, and Uplizna surged 37%, 38%, and 90% in Q2 2026.
  • Amgen presented Repatha VESALIUS-CV data for ESC August 2026, expanding cardiovascular adoption.

What critics are saying

  • FDA proposed withdrawing Tavneos on April 27, 2026; EMA echoed revocation on June 26.
  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy franchise.
  • Harbour BioMed won a June 2026 willful patent verdict; MariTide failure would crush growth.

What makes Amgen unique

  • Amgen’s portfolio spans cardiovascular, bone, immunology, oncology, and biosimilars.
  • MariTide targets monthly or less frequent obesity dosing, unlike weekly GLP-1 rivals.
  • Amgen runs seven research labs plus Hyderabad’s 2027 science and innovation center.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.

PR Newswire
Aug 12th, 2026
Amgen to open new science and innovation centre in Hyderabad's Genome Valley

Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.

Yahoo Finance
Aug 9th, 2026
Amgen fair value rises to $372 after Q2 beat sparks analyst target hikes to $450

Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.

Yahoo Finance
Aug 5th, 2026
Amgen beats Q2 forecast with $10.05B revenue, raises 2026 outlook despite obesity drug setback

Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.